FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132809780> ?p ?o ?g. }

• W3132809780 endingPage "e0009294" @default.
• W3132809780 startingPage "e0009294" @default.
• W3132809780 abstract "Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite Wuchereria bancrofti from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with Brugia timori infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with B . timori Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 subjects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant’s home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25/28, 89% vs. 8/27, 30%, P < 0.001). By 12 months after treatment, only one of 27 IDA recipients had Mf in their blood (4%) vs. 10 of 25 (40%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing B . timori Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis. Trial Registration: NCT02899936 ." @default.
• W3132809780 created "2021-03-01" @default.
• W3132809780 creator A5002622050 @default.
• W3132809780 creator A5014469195 @default.
• W3132809780 creator A5014550438 @default.
• W3132809780 creator A5019935052 @default.
• W3132809780 creator A5036900827 @default.
• W3132809780 creator A5039385312 @default.
• W3132809780 creator A5066743636 @default.
• W3132809780 creator A5068833971 @default.
• W3132809780 creator A5070652296 @default.
• W3132809780 creator A5076771599 @default.
• W3132809780 creator A5079851928 @default.
• W3132809780 creator A5082876035 @default.
• W3132809780 creator A5086651394 @default.
• W3132809780 date "2021-03-29" @default.
• W3132809780 modified "2023-10-16" @default.
• W3132809780 title "An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia" @default.
• W3132809780 cites W1603923864 @default.
• W3132809780 cites W2024682127 @default.
• W3132809780 cites W2055816465 @default.
• W3132809780 cites W2056096733 @default.
• W3132809780 cites W2059762238 @default.
• W3132809780 cites W2181101964 @default.
• W3132809780 cites W2204196017 @default.
• W3132809780 cites W2402860972 @default.
• W3132809780 cites W2472970617 @default.
• W3132809780 cites W2608390015 @default.
• W3132809780 cites W2803353483 @default.
• W3132809780 cites W2899911624 @default.
• W3132809780 cites W2951495492 @default.
• W3132809780 cites W3032069601 @default.
• W3132809780 doi "https://doi.org/10.1371/journal.pntd.0009294" @default.
• W3132809780 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8031952" @default.
• W3132809780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33780481" @default.
• W3132809780 hasPublicationYear "2021" @default.
• W3132809780 type Work @default.
• W3132809780 sameAs 3132809780 @default.
• W3132809780 citedByCount "9" @default.
• W3132809780 countsByYear W31328097802021 @default.
• W3132809780 countsByYear W31328097802022 @default.
• W3132809780 countsByYear W31328097802023 @default.
• W3132809780 crossrefType "journal-article" @default.
• W3132809780 hasAuthorship W3132809780A5002622050 @default.
• W3132809780 hasAuthorship W3132809780A5014469195 @default.
• W3132809780 hasAuthorship W3132809780A5014550438 @default.
• W3132809780 hasAuthorship W3132809780A5019935052 @default.
• W3132809780 hasAuthorship W3132809780A5036900827 @default.
• W3132809780 hasAuthorship W3132809780A5039385312 @default.
• W3132809780 hasAuthorship W3132809780A5066743636 @default.
• W3132809780 hasAuthorship W3132809780A5068833971 @default.
• W3132809780 hasAuthorship W3132809780A5070652296 @default.
• W3132809780 hasAuthorship W3132809780A5076771599 @default.
• W3132809780 hasAuthorship W3132809780A5079851928 @default.
• W3132809780 hasAuthorship W3132809780A5082876035 @default.
• W3132809780 hasAuthorship W3132809780A5086651394 @default.
• W3132809780 hasBestOaLocation W31328097801 @default.
• W3132809780 hasConcept C126322002 @default.
• W3132809780 hasConcept C141071460 @default.
• W3132809780 hasConcept C165901193 @default.
• W3132809780 hasConcept C197934379 @default.
• W3132809780 hasConcept C203014093 @default.
• W3132809780 hasConcept C2776158911 @default.
• W3132809780 hasConcept C2776908094 @default.
• W3132809780 hasConcept C2777065887 @default.
• W3132809780 hasConcept C2777411658 @default.
• W3132809780 hasConcept C2777499811 @default.
• W3132809780 hasConcept C2777629521 @default.
• W3132809780 hasConcept C2778375690 @default.
• W3132809780 hasConcept C2778672586 @default.
• W3132809780 hasConcept C42972112 @default.
• W3132809780 hasConcept C71924100 @default.
• W3132809780 hasConceptScore W3132809780C126322002 @default.
• W3132809780 hasConceptScore W3132809780C141071460 @default.
• W3132809780 hasConceptScore W3132809780C165901193 @default.
• W3132809780 hasConceptScore W3132809780C197934379 @default.
• W3132809780 hasConceptScore W3132809780C203014093 @default.
• W3132809780 hasConceptScore W3132809780C2776158911 @default.
• W3132809780 hasConceptScore W3132809780C2776908094 @default.
• W3132809780 hasConceptScore W3132809780C2777065887 @default.
• W3132809780 hasConceptScore W3132809780C2777411658 @default.
• W3132809780 hasConceptScore W3132809780C2777499811 @default.
• W3132809780 hasConceptScore W3132809780C2777629521 @default.
• W3132809780 hasConceptScore W3132809780C2778375690 @default.
• W3132809780 hasConceptScore W3132809780C2778672586 @default.
• W3132809780 hasConceptScore W3132809780C42972112 @default.
• W3132809780 hasConceptScore W3132809780C71924100 @default.
• W3132809780 hasFunder F4320306137 @default.
• W3132809780 hasIssue "3" @default.
• W3132809780 hasLocation W31328097801 @default.
• W3132809780 hasLocation W31328097802 @default.
• W3132809780 hasLocation W31328097803 @default.
• W3132809780 hasOpenAccess W3132809780 @default.
• W3132809780 hasPrimaryLocation W31328097801 @default.
• W3132809780 hasRelatedWork W1982938879 @default.
• W3132809780 hasRelatedWork W2003861955 @default.
• W3132809780 hasRelatedWork W2011436790 @default.
• W3132809780 hasRelatedWork W2016845737 @default.

• next